The short answer
Demand for incretin compounds has produced a substantial counterfeit market. The MHRA has seized counterfeit GLP-1 pens and closed an unlicensed manufacturing facility, and US poison centres reported a 265% rise in related exposures. For anyone sourcing material, third-party analytical verification is the only meaningful check.
Key facts
- MHRA action
- Counterfeit pen seizures; unlicensed facility closed
- US poison-centre exposures
- Reported 265% rise
- Primary risk
- Unknown identity, purity and content
- Practical check
- Batch-specific third-party CoA
- Identity method
- Mass spectrometry
- Purity method
- Reverse-phase HPLC
What the counterfeit market actually looks like
Counterfeiting has followed demand into the incretin space, and the failure modes are not exotic. Product may contain a different compound entirely, a fraction of the stated content, or material of unknown purity carrying synthesis by-products. Presentation is frequently convincing; packaging and holograms are much easier to reproduce than the molecule inside.
Why certificates are the practical defence
A certificate of analysis is only worth anything if it is batch-specific, issued by an independent laboratory, and matched to the lot number on the vial in front of you. A generic certificate with no batch reference proves nothing about the material you hold. The two analyses that matter are mass spectrometry, which confirms the compound is what it claims to be, and reverse-phase HPLC, which quantifies how much of the sample is that compound rather than something else.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Reading a certificate properly
Check that the batch number matches the vial. Check the issuing laboratory is independent of the supplier. Check the observed mass against the theoretical mass for the sequence. Check the HPLC purity figure and, just as much, look at whether the chromatogram is shown at all. A purity number with no trace behind it is an assertion, not a measurement.
- Batch number on the certificate matches the batch on the vial
- Issuing laboratory is independent of the supplier
- Observed mass matches theoretical mass for the stated sequence
- HPLC purity is supported by a visible chromatogram, not just a figure
- Date of issue is consistent with the batch, not years old
Why this matters more for incretins than for other compounds
Two reasons. Incretin peptides carry the highest unit value in the category, which is what attracts counterfeiting in the first place. And retatrutide in particular has no licensed product anywhere in the world, so there is no authorised reference presentation to compare an unfamiliar vial against.
Frequently asked questions
How can I tell a counterfeit from packaging?
Generally you cannot. Packaging is the easiest part to reproduce convincingly. Batch-matched analytical data is the only check that reflects what is actually in the vial.
What does a mass spectrometry result tell me?
It confirms identity, meaning that the observed molecular mass corresponds to the expected sequence. It does not by itself tell you how pure the sample is.
Is a supplier's own certificate enough?
An in-house certificate is weaker evidence than an independent one. Independence of the issuing laboratory is part of what makes the document meaningful.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Orforglipron in the UK: Access, Cost and the NHS QuestionFoundayo is available in the UK on private prescription only, reported at roughly £99-£179 a month. NHS funding awaits NICE guidance expected 18 November 2026.
- Orforglipron: Reported Side Effects and TolerabilityNausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain are most commonly reported. Why the profile is a GLP-1 class effect, not a surprise.
- How NICE Decides Whether the NHS Funds a MedicineLicensing and funding are separate decisions. How NICE appraisal works, why obesity medicines are difficult cases, and what is expected on 18 November 2026.
- CagriSema FDA Filing: Where the Review StandsNovo Nordisk filed CagriSema with the FDA in December 2025 on the REDEFINE programme. A decision is expected in Q4 2026. What the trials reported.
- TRIUMPH-5: The Retatrutide vs Tirzepatide Head-to-HeadTRIUMPH-5 randomises 800 adults to retatrutide or tirzepatide over Phase 3. Primary completion is November 2026 - the first direct comparison of the two.